Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade

Pei Ling Chen, Whijae Roh, Alexandre Reuben, Zachary A. Cooper, Christine N. Spencer, Peter A. Prieto, John P. Miller, Roland L. Bassett, Vancheswaran Gopalakrishnan, Khalida Wani, Mariana Petaccia De Macedo, Jacob L. Austin-Breneman, Hong Jiang, Qing Chang, Sangeetha M. Reddy, Wei Shen Chen, Michael T. Tetzlaff, Russell J. Broaddus, Michael A. Davies, Jeffrey E. GershenwaldLauren Haydu, Alexander J. Lazar, Sapna P. Patel, Patrick Hwu, Wen Jen Hwu, Adi Diab, Isabella C. Glitza, Scott E. Woodman, Luis M. Vence, Ignacio I. Wistuba, Rodabe N. Amaria, Lawrence N. Kwong, Victor Prieto, R. Eric Davis, Wencai Ma, Willem W. Overwijk, Arlene H. Sharpe, Jianhua Hu, P. Andrew Futreal, Jorge Blando, Padmanee Sharma, James P. Allison, Lynda Chin, Jennifer A. Wargo

Research output: Contribution to journalArticle

248 Citations (Scopus)

Abstract

Immune checkpoint blockade represents a major breakthrough in cancer therapy; however, responses are not universal. Genomic and immune features in pretreatment tumor biopsies have been reported to correlate with response in patients with melanoma and other cancers, but robust biomarkers have not been identified. We studied a cohort of patients with metastatic melanoma initially treated with cytotoxic T-lymphocyte–associated antigen-4 (CTLA4) blockade (n=53) followed by programmed death-1 (PD-1) blockade at progression (n=46), and analyzed immune signatures in longitudinal tissue samples collected at multiple time points during therapy. In this study, we demonstrate that adaptive immune signatures in tumor biopsy samples obtained early during the course of treatment are highly predictive of response to immune checkpoint blockade and also demonstrate differential effects on the tumor microenvironment induced by CTLA4 and PD-1 blockade. Importantly, potential mechanisms of therapeutic resistance to immune checkpoint blockade were also identified. SIGNIFICANCE: These studies demonstrate that adaptive immune signatures in early on-treatment tumor biopsies are predictive of response to checkpoint blockade and yield insight into mechanisms of therapeutic resistance. These concepts have far-reaching implications in this age of precision medicine and should be explored in immune checkpoint blockade treatment across cancer types.

Original languageEnglish (US)
Pages (from-to)827-837
Number of pages11
JournalCancer discovery
Volume6
Issue number8
DOIs
StatePublished - Aug 2016
Externally publishedYes

Fingerprint

Biomarkers
Neoplasms
Viral Tumor Antigens
Biopsy
Therapeutics
Melanoma
Precision Medicine
Tumor Microenvironment
Tumor Biomarkers

ASJC Scopus subject areas

  • Oncology

Cite this

Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. / Chen, Pei Ling; Roh, Whijae; Reuben, Alexandre; Cooper, Zachary A.; Spencer, Christine N.; Prieto, Peter A.; Miller, John P.; Bassett, Roland L.; Gopalakrishnan, Vancheswaran; Wani, Khalida; De Macedo, Mariana Petaccia; Austin-Breneman, Jacob L.; Jiang, Hong; Chang, Qing; Reddy, Sangeetha M.; Chen, Wei Shen; Tetzlaff, Michael T.; Broaddus, Russell J.; Davies, Michael A.; Gershenwald, Jeffrey E.; Haydu, Lauren; Lazar, Alexander J.; Patel, Sapna P.; Hwu, Patrick; Hwu, Wen Jen; Diab, Adi; Glitza, Isabella C.; Woodman, Scott E.; Vence, Luis M.; Wistuba, Ignacio I.; Amaria, Rodabe N.; Kwong, Lawrence N.; Prieto, Victor; Eric Davis, R.; Ma, Wencai; Overwijk, Willem W.; Sharpe, Arlene H.; Hu, Jianhua; Andrew Futreal, P.; Blando, Jorge; Sharma, Padmanee; Allison, James P.; Chin, Lynda; Wargo, Jennifer A.

In: Cancer discovery, Vol. 6, No. 8, 08.2016, p. 827-837.

Research output: Contribution to journalArticle

Chen, PL, Roh, W, Reuben, A, Cooper, ZA, Spencer, CN, Prieto, PA, Miller, JP, Bassett, RL, Gopalakrishnan, V, Wani, K, De Macedo, MP, Austin-Breneman, JL, Jiang, H, Chang, Q, Reddy, SM, Chen, WS, Tetzlaff, MT, Broaddus, RJ, Davies, MA, Gershenwald, JE, Haydu, L, Lazar, AJ, Patel, SP, Hwu, P, Hwu, WJ, Diab, A, Glitza, IC, Woodman, SE, Vence, LM, Wistuba, II, Amaria, RN, Kwong, LN, Prieto, V, Eric Davis, R, Ma, W, Overwijk, WW, Sharpe, AH, Hu, J, Andrew Futreal, P, Blando, J, Sharma, P, Allison, JP, Chin, L & Wargo, JA 2016, 'Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade', Cancer discovery, vol. 6, no. 8, pp. 827-837. https://doi.org/10.1158/2159-8290.CD-15-1545
Chen, Pei Ling ; Roh, Whijae ; Reuben, Alexandre ; Cooper, Zachary A. ; Spencer, Christine N. ; Prieto, Peter A. ; Miller, John P. ; Bassett, Roland L. ; Gopalakrishnan, Vancheswaran ; Wani, Khalida ; De Macedo, Mariana Petaccia ; Austin-Breneman, Jacob L. ; Jiang, Hong ; Chang, Qing ; Reddy, Sangeetha M. ; Chen, Wei Shen ; Tetzlaff, Michael T. ; Broaddus, Russell J. ; Davies, Michael A. ; Gershenwald, Jeffrey E. ; Haydu, Lauren ; Lazar, Alexander J. ; Patel, Sapna P. ; Hwu, Patrick ; Hwu, Wen Jen ; Diab, Adi ; Glitza, Isabella C. ; Woodman, Scott E. ; Vence, Luis M. ; Wistuba, Ignacio I. ; Amaria, Rodabe N. ; Kwong, Lawrence N. ; Prieto, Victor ; Eric Davis, R. ; Ma, Wencai ; Overwijk, Willem W. ; Sharpe, Arlene H. ; Hu, Jianhua ; Andrew Futreal, P. ; Blando, Jorge ; Sharma, Padmanee ; Allison, James P. ; Chin, Lynda ; Wargo, Jennifer A. / Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. In: Cancer discovery. 2016 ; Vol. 6, No. 8. pp. 827-837.
@article{67b3418018c44901903cb7bf7f683b69,
title = "Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade",
abstract = "Immune checkpoint blockade represents a major breakthrough in cancer therapy; however, responses are not universal. Genomic and immune features in pretreatment tumor biopsies have been reported to correlate with response in patients with melanoma and other cancers, but robust biomarkers have not been identified. We studied a cohort of patients with metastatic melanoma initially treated with cytotoxic T-lymphocyte–associated antigen-4 (CTLA4) blockade (n=53) followed by programmed death-1 (PD-1) blockade at progression (n=46), and analyzed immune signatures in longitudinal tissue samples collected at multiple time points during therapy. In this study, we demonstrate that adaptive immune signatures in tumor biopsy samples obtained early during the course of treatment are highly predictive of response to immune checkpoint blockade and also demonstrate differential effects on the tumor microenvironment induced by CTLA4 and PD-1 blockade. Importantly, potential mechanisms of therapeutic resistance to immune checkpoint blockade were also identified. SIGNIFICANCE: These studies demonstrate that adaptive immune signatures in early on-treatment tumor biopsies are predictive of response to checkpoint blockade and yield insight into mechanisms of therapeutic resistance. These concepts have far-reaching implications in this age of precision medicine and should be explored in immune checkpoint blockade treatment across cancer types.",
author = "Chen, {Pei Ling} and Whijae Roh and Alexandre Reuben and Cooper, {Zachary A.} and Spencer, {Christine N.} and Prieto, {Peter A.} and Miller, {John P.} and Bassett, {Roland L.} and Vancheswaran Gopalakrishnan and Khalida Wani and {De Macedo}, {Mariana Petaccia} and Austin-Breneman, {Jacob L.} and Hong Jiang and Qing Chang and Reddy, {Sangeetha M.} and Chen, {Wei Shen} and Tetzlaff, {Michael T.} and Broaddus, {Russell J.} and Davies, {Michael A.} and Gershenwald, {Jeffrey E.} and Lauren Haydu and Lazar, {Alexander J.} and Patel, {Sapna P.} and Patrick Hwu and Hwu, {Wen Jen} and Adi Diab and Glitza, {Isabella C.} and Woodman, {Scott E.} and Vence, {Luis M.} and Wistuba, {Ignacio I.} and Amaria, {Rodabe N.} and Kwong, {Lawrence N.} and Victor Prieto and {Eric Davis}, R. and Wencai Ma and Overwijk, {Willem W.} and Sharpe, {Arlene H.} and Jianhua Hu and {Andrew Futreal}, P. and Jorge Blando and Padmanee Sharma and Allison, {James P.} and Lynda Chin and Wargo, {Jennifer A.}",
year = "2016",
month = "8",
doi = "10.1158/2159-8290.CD-15-1545",
language = "English (US)",
volume = "6",
pages = "827--837",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade

AU - Chen, Pei Ling

AU - Roh, Whijae

AU - Reuben, Alexandre

AU - Cooper, Zachary A.

AU - Spencer, Christine N.

AU - Prieto, Peter A.

AU - Miller, John P.

AU - Bassett, Roland L.

AU - Gopalakrishnan, Vancheswaran

AU - Wani, Khalida

AU - De Macedo, Mariana Petaccia

AU - Austin-Breneman, Jacob L.

AU - Jiang, Hong

AU - Chang, Qing

AU - Reddy, Sangeetha M.

AU - Chen, Wei Shen

AU - Tetzlaff, Michael T.

AU - Broaddus, Russell J.

AU - Davies, Michael A.

AU - Gershenwald, Jeffrey E.

AU - Haydu, Lauren

AU - Lazar, Alexander J.

AU - Patel, Sapna P.

AU - Hwu, Patrick

AU - Hwu, Wen Jen

AU - Diab, Adi

AU - Glitza, Isabella C.

AU - Woodman, Scott E.

AU - Vence, Luis M.

AU - Wistuba, Ignacio I.

AU - Amaria, Rodabe N.

AU - Kwong, Lawrence N.

AU - Prieto, Victor

AU - Eric Davis, R.

AU - Ma, Wencai

AU - Overwijk, Willem W.

AU - Sharpe, Arlene H.

AU - Hu, Jianhua

AU - Andrew Futreal, P.

AU - Blando, Jorge

AU - Sharma, Padmanee

AU - Allison, James P.

AU - Chin, Lynda

AU - Wargo, Jennifer A.

PY - 2016/8

Y1 - 2016/8

N2 - Immune checkpoint blockade represents a major breakthrough in cancer therapy; however, responses are not universal. Genomic and immune features in pretreatment tumor biopsies have been reported to correlate with response in patients with melanoma and other cancers, but robust biomarkers have not been identified. We studied a cohort of patients with metastatic melanoma initially treated with cytotoxic T-lymphocyte–associated antigen-4 (CTLA4) blockade (n=53) followed by programmed death-1 (PD-1) blockade at progression (n=46), and analyzed immune signatures in longitudinal tissue samples collected at multiple time points during therapy. In this study, we demonstrate that adaptive immune signatures in tumor biopsy samples obtained early during the course of treatment are highly predictive of response to immune checkpoint blockade and also demonstrate differential effects on the tumor microenvironment induced by CTLA4 and PD-1 blockade. Importantly, potential mechanisms of therapeutic resistance to immune checkpoint blockade were also identified. SIGNIFICANCE: These studies demonstrate that adaptive immune signatures in early on-treatment tumor biopsies are predictive of response to checkpoint blockade and yield insight into mechanisms of therapeutic resistance. These concepts have far-reaching implications in this age of precision medicine and should be explored in immune checkpoint blockade treatment across cancer types.

AB - Immune checkpoint blockade represents a major breakthrough in cancer therapy; however, responses are not universal. Genomic and immune features in pretreatment tumor biopsies have been reported to correlate with response in patients with melanoma and other cancers, but robust biomarkers have not been identified. We studied a cohort of patients with metastatic melanoma initially treated with cytotoxic T-lymphocyte–associated antigen-4 (CTLA4) blockade (n=53) followed by programmed death-1 (PD-1) blockade at progression (n=46), and analyzed immune signatures in longitudinal tissue samples collected at multiple time points during therapy. In this study, we demonstrate that adaptive immune signatures in tumor biopsy samples obtained early during the course of treatment are highly predictive of response to immune checkpoint blockade and also demonstrate differential effects on the tumor microenvironment induced by CTLA4 and PD-1 blockade. Importantly, potential mechanisms of therapeutic resistance to immune checkpoint blockade were also identified. SIGNIFICANCE: These studies demonstrate that adaptive immune signatures in early on-treatment tumor biopsies are predictive of response to checkpoint blockade and yield insight into mechanisms of therapeutic resistance. These concepts have far-reaching implications in this age of precision medicine and should be explored in immune checkpoint blockade treatment across cancer types.

UR - http://www.scopus.com/inward/record.url?scp=84982946696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982946696&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-15-1545

DO - 10.1158/2159-8290.CD-15-1545

M3 - Article

C2 - 27301722

AN - SCOPUS:84982946696

VL - 6

SP - 827

EP - 837

JO - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 8

ER -